Back

Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs

Roys, H.; Arykbayeva, A.; Friedman, S. K.; Gifford, G.; Palmer, E. R.; Rogers, A.; Tran, E. N. H.; Fry, L. G.; Weaver, A.; Bowlin, A. K.; Jones, M. D.; Eledge, M.; Boehme, K. W.; Naumiec, G. R.; Weinkopff, T.

2024-08-24 microbiology
10.1101/2024.08.23.605637 bioRxiv
Show abstract

An increasing number of treatment failures with current pharmaceutics, as well as a lack of a vaccine, demonstrates the need to develop new treatment options for leishmaniasis. Herein, we describe the synthesis and in vitro analysis of 24 disquaramide compounds targeting the Leishmania major parasite. Of the compounds that were evaluated, six of them (13, 19, 20, 22, 24, and 26) were capable of significantly decreasing the number of parasites by up to 42% compared to the control by day four. This demonstrates that disquaramides either impair parasite replication or have leishmancidal effects. Additionally, none of the disquaramide compounds tested displayed host cell cytotoxicity. These experiments provide evidence that disquaramides have the potential to be effective anti-leishmanial therapeutics.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.